ArticleFrontiers in pharmacology2026
Yiqi Huoxue Yangyin Decoction attenuates diabetic nephropathy in
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic nephropathy (DN) is a major complication of diabetes with limited therapeutic options. Yiqi Huoxue Yangyin Decoction (YHY), a traditional Chinese medicine formula designed to treat the TCM syndrome of "Qi and Yin deficiency with blood stasis" often observed in DN, has shown clinical potential. However, its precise mechanism of action, particularly concerning the regulation of podocyte autophagy, remains unclear. Methods: The chemical profile of YHY was characterized using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). The therapeutic effects and mechanisms were evaluated in a Results: UPLC-MS/MS analysis successfully identified multiple chemical metabolites in YHY, providing a comprehensive phytochemical profile of the formula. Treatment with YHY significantly ameliorated renal dysfunction and attenuated podocyte injury in Conclusion: YHY, a traditional Chinese medicine formula with defined chemical metabolites, ameliorates podocyte damage in DN by activating autophagy via the METTL3-m6A-mTOR signaling pathway. This study provides novel insights into the epigenetic regulation of DN and underscores the potential of YHY as a therapeutic agent for this condition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.